211 related articles for article (PubMed ID: 26542126)
21. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
22. PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells.
Smith AG; Beaumont KA; Smit DJ; Thurber AE; Cook AL; Boyle GM; Parsons PG; Sturm RA; Muscat GE
Int J Biochem Cell Biol; 2009 Apr; 41(4):844-52. PubMed ID: 18822385
[TBL] [Abstract][Full Text] [Related]
23. New thiazolidinediones affect endothelial cell activation and angiogenesis.
Rudnicki M; Tripodi GL; Ferrer R; Boscá L; Pitta MG; Pitta IR; Abdalla DS
Eur J Pharmacol; 2016 Jul; 782():98-106. PubMed ID: 27108791
[TBL] [Abstract][Full Text] [Related]
24. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
25. Vascular effects of PPARgamma activators - from bench to bedside.
Marx N; Walcher D
Prog Lipid Res; 2007 Nov; 46(6):283-96. PubMed ID: 17637478
[TBL] [Abstract][Full Text] [Related]
26. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R.
Ferruzzi P; Ceni E; Tarocchi M; Grappone C; Milani S; Galli A; Fiorelli G; Serio M; Mannelli M
J Clin Endocrinol Metab; 2005 Mar; 90(3):1332-9. PubMed ID: 15585569
[TBL] [Abstract][Full Text] [Related]
27. Insulin resistance and PPAR insulin sensitizers.
Bhatia V; Viswanathan P
Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
[TBL] [Abstract][Full Text] [Related]
28. Rosiglitazone inhibits insulin-like growth factor‑1-induced polycystic kidney disease cell growth and p70S6 kinase activation.
Liu C; Zhang Y; Yuan L; Fu L; Mei C
Mol Med Rep; 2013 Sep; 8(3):861-4. PubMed ID: 23864113
[TBL] [Abstract][Full Text] [Related]
29. Chemical Synthesis, Mechanism of Action and Anticancer Potential of Medicinally Important Thiazolidin-2,4-dione Derivatives: A Review.
Kumar H; Deep A; Marwaha RK
Mini Rev Med Chem; 2019; 19(18):1474-1516. PubMed ID: 31092179
[TBL] [Abstract][Full Text] [Related]
30. Peroxisome proliferator-activating receptors: a new way to treat melanoma?
Schadendorf D
J Invest Dermatol; 2009 May; 129(5):1061-3. PubMed ID: 19369932
[TBL] [Abstract][Full Text] [Related]
31. Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation.
Betz MJ; Shapiro I; Fassnacht M; Hahner S; Reincke M; Beuschlein F;
J Clin Endocrinol Metab; 2005 Jul; 90(7):3886-96. PubMed ID: 15886257
[TBL] [Abstract][Full Text] [Related]
32. Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer.
Ferrari SM; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A; Fallahi P
Curr Med Chem; 2016; 23(7):636-49. PubMed ID: 26844838
[TBL] [Abstract][Full Text] [Related]
33. Anti-proliferative effect of rosiglitazone in the human T-lymphocyte leukaemia cell line Jurkat cells.
Wei R; Yu F; Yang J; Gao H; Wang H; Hong T
Cell Biol Int; 2018 May; 42(5):515-524. PubMed ID: 29274299
[TBL] [Abstract][Full Text] [Related]
34. Functional role of peroxisome-proliferator-activated receptor γ in hepatocellular carcinoma.
Wu CW; Farrell GC; Yu J
J Gastroenterol Hepatol; 2012 Nov; 27(11):1665-9. PubMed ID: 22742931
[TBL] [Abstract][Full Text] [Related]
35. PPARγ agonist suppresses TLR4 expression and TNF-α production in LPS stimulated monocyte leukemia cells.
Wang CZ; Zhang Y; Li XD; Hu Y; Fang ZG; Lin DJ; Xiao RZ; Huang RW; Huang HQ; Liu PQ; Liu JJ
Cell Biochem Biophys; 2011 Jul; 60(3):167-72. PubMed ID: 21104157
[TBL] [Abstract][Full Text] [Related]
36. Thiazolidine-2,4-diones: progress towards multifarious applications.
Jain VS; Vora DK; Ramaa CS
Bioorg Med Chem; 2013 Apr; 21(7):1599-620. PubMed ID: 23419324
[TBL] [Abstract][Full Text] [Related]
37. Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) as a Target for Concurrent Management of Diabetes and Obesity-Related Cancer.
Wang Q; Imam MU; Yida Z; Wang F
Curr Pharm Des; 2017; 23(25):3677-3688. PubMed ID: 28677503
[TBL] [Abstract][Full Text] [Related]
38. A new dawn for the use of thiazolidinediones in cancer therapy.
Joshi H; Pal T; Ramaa CS
Expert Opin Investig Drugs; 2014 Apr; 23(4):501-10. PubMed ID: 24597633
[TBL] [Abstract][Full Text] [Related]
39. PPAR-gamma in ulcerative colitis: a novel target for intervention.
Bertin B; Dubuquoy L; Colombel JF; Desreumaux P
Curr Drug Targets; 2013 Nov; 14(12):1501-7. PubMed ID: 23651165
[TBL] [Abstract][Full Text] [Related]
40. [Effects of PPARgamma agonist on dyslipidemia and atherosclerosis].
Komatsu A; Node K
Nihon Rinsho; 2010 Feb; 68(2):294-8. PubMed ID: 20158099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
